<DOC>
	<DOCNO>NCT00543439</DOCNO>
	<brief_summary>The purpose research study determine effectiveness , safety , pharmacokinetics ( PK ) moroctocog alfa ( AF-CC ) previously treat subject , young 6 year age , severe moderately severe hemophilia A .</brief_summary>
	<brief_title>Study Evaluating Prophylaxis Treatment &amp; Characterizing Efficacy , Safety , &amp; PK Of B-Domain Deleted Recombinant FVIII</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subject , age less 6 year , moderately severe severe hemophilia A . A negative FVIII inhibitor titer screening , medical history negative past FVIII inhibitor . At least 20 exposure day FVIII replacement product . Adequate hepatic renal function CD4 count &gt; 400 cells/uL , receive antiviral therapy must stable regimen Additional criterion subject participate PK assessment : Male subject describe immediately except must FVIII Activity less equal 1 % confirmed central laboratory screen test Age &lt; 6 year time PK assessment . The subject 's size sufficient permit PKrelated phlebotomy . The subject able comply procedure conduct PK assessment , include mandatory 72hour washout period precede PK assessment . A history FVIII inhibitor . Presence bleed disorder addition hemophilia A . Treatment investigational drug device within 30 day time signing informed consent form . Major orthopedic surgery plan occur course study . Regular ( e.g. , daily , every day ) use antifibrinolytic agent medication know influence platelet function aspirin certain nonsteroidal antiinflammatory drug ( NSAIDs ) , regular , concomitant therapy immunomodulating drug ( e.g. , intravenous immunoglobulin [ IVIG ] , routine systemic corticosteroid ) . Known hypersensitivity hamster protein .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>